Therapeutic drug monitoring in inflammatory bowel disease patients switching from intravenous to subcutaneous infliximab: insights from a prospective real-world study

Key Points

• To evaluate the safety and efficacy of switching infliximab administration routes in patients with inflammatory bowel disease.
• Prospective real-world study design
• Patients were switched from intravenous infliximab to subcutaneous infliximab
• Dosing guided by previous intravenous regimen and serum drug concentrations
• Patients safely transitioned to subcutaneous infliximab treatment
• Initial dosing based on prior intravenous regimen was effective
• Fixed subcutaneous dosing may be unreliable for patients previously treated with higher intravenous doses